• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Oppenheimer Appoints James Yoo Managing Director in Healthcare Equity Capital Markets Investment Banking

    10/6/25 6:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance
    Get the next $OPY alert in real time by email

    Seasoned industry professional brings 27 years of experience to expanding Healthcare platform

    NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer") — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE:OPY) — today announced that James Yoo has been named a Managing Director within its Healthcare Equity Capital Markets Investment Banking Group. In this role, Mr. Yoo will focus on Biotechnology Equity Capital Markets transactions.

    With 27 years of experience, Mr. Yoo has developed deep expertise in a range of financing structures, including Private Investment in Public Equity (PIPEs), Follow-on Offerings, Confidentially Marketed Public Offerings (CMPOs) and Registered Direct transactions.

    "James brings an exceptional track record of execution and deep relationships across the biotechnology investment community to his new role," said Peter Bennett, Managing Director and Head of Equity Capital Markets Investment Banking at Oppenheimer. "His ability to navigate complex financing structures will further strengthen Oppenheimer's leadership in Healthcare Equity Capital Markets."

    Before stepping into his new role, Mr. Yoo served as the Healthcare Specialist on Oppenheimer's Sales & Trading Desk since 2023, advising healthcare-dedicated investment funds and early- and late-stage biotechnology companies. Prior to Oppenheimer, he held various positions at leading firms such as Piper Sandler, Mizuho, and Nomura.

    "I am honored to join Oppenheimer's Healthcare Equity Capital Markets Investment Banking Group at such an exciting time for the biotechnology sector," Yoo said. "The firm's collaborative culture and broad platform create an exceptional environment to deliver innovative capital markets solutions. I look forward to working with my colleagues to help biotech companies access the financing they need to advance groundbreaking science and improve patient outcomes."

    About Oppenheimer Holdings Inc.

    Oppenheimer Holdings Inc., through its Oppenheimer & Co. Inc. subsidiary, and related entities, provides a full range of wealth management, securities brokerage, and investment banking services to high-net-worth individuals, families, corporate executives, businesses, and institutions. For more information, please visit www.oppenheimer.com.

    Media Contact:

    Joseph Kuo / Michael Dugan

    Haven Tower Group LLC

    424 317 4851 or 424 317 4852

    [email protected] or [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/oppenheimer-appoints-james-yoo-managing-director-in-healthcare-equity-capital-markets-investment-banking-302574286.html

    SOURCE Oppenheimer & Co. Inc.

    Get the next $OPY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPY
    SEC Filings

    View All

    Oppenheimer Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - OPPENHEIMER HOLDINGS INC (0000791963) (Filer)

    12/12/25 8:13:58 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OPPENHEIMER HOLDINGS INC (0000791963) (Filer)

    11/3/25 10:16:53 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OPPENHEIMER HOLDINGS INC (0000791963) (Filer)

    10/31/25 8:38:56 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    $OPY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OPPENHEIMER HOLDINGS INC. DECLARES SPECIAL DIVIDEND

    NEW YORK, Dec. 12, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE:OPY) today announced that its Board of Directors has declared a special cash dividend on OPY Class A non-voting and Class B voting common stock of $1.00 per share, payable January 9, 2026, to shareholders of record as of the close of business on December 26, 2025. The aggregate payment will be approximately $10.5 million. The special dividend will be funded through OPY's existing cash management activities. Robert S. Lowenthal, President and Chief Executive Officer, commented: "We are pleased to recognize the year's operating results and our improved financial position through the announcement of a special dividend of $1

    12/12/25 8:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.

    The addition of well-respected biotech expert strengthens one of Oppenheimer's longest-standing franchise areas NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE:OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City. Biliouris comes to Oppenheimer from BMO Capital Markets, where he was a Director, mainly covering the genetic medicines space. Before BMO, he was a VP in Biotech Research at Morgan Stanley and worked in drug development and produc

    12/8/25 6:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer & Co. Inc. Appoints Keith Peterson As Head of Cash Equity Sales and Trading

    Veteran equity markets leader joins to oversee trading operations and advance cross-platform growth initiatives NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. – a leading investment bank, wealth manager, and subsidiary of Oppenheimer Holdings (NYSE:OPY) — today announced that Keith Peterson has joined the firm as Managing Director and Head of Cash Equity Sales and Trading. He will report to John Hellier, Senior Managing Director and Head of Equities. In this role, Peterson will oversee all supervisory and operational activities for Oppenheimer's equity sales and trading team, working closely with other leaders in the Equities division and across the firm to ensure continued

    11/17/25 6:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    $OPY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Secretary Mcnamara Dennis P sold $147,620 worth of Class A non-voting common stock (2,000 units at $73.81), decreasing direct ownership by 8% to 21,766 units (SEC Form 4)

    4 - OPPENHEIMER HOLDINGS INC (0000791963) (Issuer)

    8/6/25 11:16:49 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Director Friedman Paul M sold $443,199 worth of Class A non-voting common stock (7,000 units at $63.31) (SEC Form 4)

    4 - OPPENHEIMER HOLDINGS INC (0000791963) (Issuer)

    6/10/25 5:27:25 PM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Director Friedman Paul M sold $189,320 worth of Class A non-voting common stock (3,000 units at $63.11) (SEC Form 4)

    4 - OPPENHEIMER HOLDINGS INC (0000791963) (Issuer)

    6/9/25 4:03:38 PM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    $OPY
    Leadership Updates

    Live Leadership Updates

    View All

    Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.

    The addition of well-respected biotech expert strengthens one of Oppenheimer's longest-standing franchise areas NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE:OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City. Biliouris comes to Oppenheimer from BMO Capital Markets, where he was a Director, mainly covering the genetic medicines space. Before BMO, he was a VP in Biotech Research at Morgan Stanley and worked in drug development and produc

    12/8/25 6:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer & Co. Inc. Appoints Keith Peterson As Head of Cash Equity Sales and Trading

    Veteran equity markets leader joins to oversee trading operations and advance cross-platform growth initiatives NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. – a leading investment bank, wealth manager, and subsidiary of Oppenheimer Holdings (NYSE:OPY) — today announced that Keith Peterson has joined the firm as Managing Director and Head of Cash Equity Sales and Trading. He will report to John Hellier, Senior Managing Director and Head of Equities. In this role, Peterson will oversee all supervisory and operational activities for Oppenheimer's equity sales and trading team, working closely with other leaders in the Equities division and across the firm to ensure continued

    11/17/25 6:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer Announces the Appointment of Public Finance Banker Guy T. Logan as Managing Director, Head of Infrastructure & Mid-Atlantic Region

    Addition of respected industry veteran highlights the rapid expansion of the firm's Public Finance team NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer"), a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE:OPY), today announced it has hired Guy T. Logan to serve as Managing Director, Head of Infrastructure & Mid-Atlantic Region within the firm's Public Finance Investment Banking Division. He will report to Beth Coolidge, Managing Director and Head of Public Finance. Logan joins Oppenheimer with more than 30 years of municipal finance experience. Over the course of his career, he has served as senior or lead banker on more th

    10/29/25 6:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    $OPY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Oppenheimer Holdings, Inc. (Amendment)

    SC 13G/A - OPPENHEIMER HOLDINGS INC (0000791963) (Subject)

    9/23/21 3:31:42 PM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Oppenheimer Holdings, Inc.

    SC 13G - OPPENHEIMER HOLDINGS INC (0000791963) (Subject)

    6/25/21 2:44:05 PM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    $OPY
    Financials

    Live finance-specific insights

    View All

    OPPENHEIMER HOLDINGS INC. DECLARES SPECIAL DIVIDEND

    NEW YORK, Dec. 12, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE:OPY) today announced that its Board of Directors has declared a special cash dividend on OPY Class A non-voting and Class B voting common stock of $1.00 per share, payable January 9, 2026, to shareholders of record as of the close of business on December 26, 2025. The aggregate payment will be approximately $10.5 million. The special dividend will be funded through OPY's existing cash management activities. Robert S. Lowenthal, President and Chief Executive Officer, commented: "We are pleased to recognize the year's operating results and our improved financial position through the announcement of a special dividend of $1

    12/12/25 8:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer Holdings Inc. Reports Third Quarter 2025 Earnings

    NEW YORK, Oct. 31, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE:OPY) (the "Company" or "Firm") today reported net income of $21.7 million or $2.06 basic earnings per share for the third quarter of 2025, compared with net income of $24.5 million or $2.38 basic earnings per share for the third quarter of 2024. Third quarter 2025 results were significantly impacted by higher pre-tax compensation expenses for liability-based awards totaling $13.5 million or $0.95 basic earnings per share (after tax), attributable to an increase in the OPY Class A share price (increased $8.30 per share during the quarter). Revenue for the third quarter of 2025 was $424.4 million, an increase of 13.7%, comp

    10/31/25 8:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Oppenheimer Holdings Inc. Reports Second Quarter 2025 Earnings

    NEW YORK, Aug. 1, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE:OPY) (the "Company" or "Firm") today reported net income of $21.7 million or $2.06 basic earnings per share for the second quarter of 2025, compared with net income of $10.3 million or $0.99 basic earnings per share for the second quarter of 2024. Revenue for the second quarter of 2025 was $373.2 million, an increase of 12.9%, compared to revenue of $330.6 million for the second quarter of 2024. Robert S. Lowenthal, President and CEO commented, "The Firm's improved operating results for the quarter showcase the strength of our businesses and the maturing of investments in experienced team members over the past several yea

    8/1/25 8:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance